Q/C TECHNOLOGIES, INC.
QCLS · XNASCIK 1321834fmd_1RV8PED7Z3X4TEZMY1T54HKCTQManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2013 to Jun 30, 2026, 54 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 3 | 3 | 2 | 2 | – | – | – | – | – | – |
| Cost of revenue | 0 | 0 | 0 | 0 | – | – | – | – | – | – |
| Gross profit | 2 | 1 | 0 | 0 | – | – | – | – | – | – |
| Realized investment gains (losses) | – | – | 0 | 0 | (0) | – | – | – | – | – |
| Research and development | 1 | 1 | 1 | 0 | 2 | 7 | 9 | 8 | 3 | 3 |
| Selling, general and administrative | 5 | 6 | 7 | 3 | 4 | – | – | – | – | – |
| Operating income | (3) | (7) | (10) | (3) | (9) | (29) | (15) | (17) | (10) | (10) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 0 | 1 | 1 | 0 | 0 | (1) | 0 | 13 | (13) | (2) |
| Income before taxes | (3) | (7) | (11) | (3) | (9) | (30) | (15) | (4) | (23) | (12) |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | (3) | (12) | – | – | – | – | – |
| Net income | (3) | (7) | (11) | (4) | (9) | (30) | (15) | (4) | (23) | (12) |
| Net income to common shareholders | 3 | 7 | 11 | – | – | – | (15) | (8) | (27) | (15) |